PARIS (Reuters) – France will tax drugmakers whose costly hepatitis C
drugs threaten to throw off course its healthcare budget, the
government has said, heaping pressure on pharmaceutical companies like
Gilead Sciences to cut their prices.
The Socialist government said
it had designed a “progressive contribution scheme” ensuring all
patients can access new and more effective treatments against the
liver-destroying virus, while limiting the burden of these drugs on
The government will selectively tax drugmakers
when the total cost to the state from their hepatitis C drugs exceeds a
certain amount each year, Health Minister Marisol Touraine said, as she
unveiled the country’s 2015 social security budget bill on Monday.